文献速递衰弱、肌少症与跌倒老年慢病共病管理多重用药

体弱与健壮居民转入长期照护机构后降糖药使用变化

Change in Use of Glucose-Lowering Medications in Frail and Robust Residents Following Hospital Discharge to Long-Term Care Facilities.
PubMed 文献 · J Am Med Dir Assoc · 2026-02-09

该回顾性队列研究纳入2012至2018年澳大利亚维多利亚州新转入长期照护机构的65岁以上2型糖尿病成人19,704例(78.7%为体弱,45.9%≥85岁,54.6%女性)。体弱居民降糖药使用率从59.7%降至54.8%,健壮居民从59.3%降至56.2%,变化主要来自二甲双胍和磺脲类减少、胰岛素增加。体弱与二甲双胍单药及二甲双胍联合磺脲类 dispensing 概率较低相关,但整体未见有意义的治疗降阶。

要点

  • 体弱居民降糖药使用率由59.7%降至54.8%,健壮居民由59.3%降至56.2%。
  • 变化主要来自二甲双胍和磺脲类减少、胰岛素增加。
  • 体弱与二甲双胍单药aRR 0.91、二甲双胍联合磺脲类aRR 0.89相关。

核心结论

  • 转入长期照护机构后90天内存在重新评估降糖方案的潜在遗漏机会。
  • 体弱状态似乎未与有意义的2型糖尿病治疗降阶相关。

研究设计与样本

  • 回顾性队列研究,纳入澳大利亚维多利亚州2012至2018年新转入长期照护机构的65岁以上2型糖尿病成人19,704例。
  • 采用链接的医院与药物dispensing数据,比较入院前90天与转出后90天降糖药使用率。
  • 使用Poisson回归估计年龄性别调整患病率,广义估计方程估计多变量调整相对风险。

主要发现

  • 体弱居民降糖药使用率从59.7%(95%CI 58.4-61.0)降至54.8%(95%CI 53.6-56.1)。
  • 健壮居民降糖药使用率从59.3%(95%CI 56.9-61.9)降至56.2%(95%CI 53.8-58.7)。
  • 变化主要归因于二甲双胍和磺脲类使用减少及胰岛素使用增加。
  • 体弱与转出后90天内二甲双胍单药dispensing概率较低相关(aRR 0.91,95%CI 0.85-0.97)。
  • 体弱与转出后90天二甲双胍联合磺脲类dispensing概率较低相关(aRR 0.89,95%CI 0.79-0.99)。

关键数值与推荐

  • 体弱居民降糖药使用率59.7%→54.8%,健壮居民59.3%→56.2%(入院前90天与转出后90天比较)。
  • 二甲双胍单药转出后90天aRR 0.91(95%CI 0.85-0.97)。
  • 二甲双胍联合磺脲类转出后90天aRR 0.89(95%CI 0.79-0.99)。
  • 6个月内未dispensing降糖药aRR 1.04(95%CI 1.02-1.07)。

临床怎么用

  • 长期照护机构接诊出院居民时,应在转出后90天内主动复核降糖方案。
  • 对体弱居民不应默认已进行降糖治疗降阶,需个体化评估治疗强度与照护目标。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hospital discharge to a long-term care facility (LTCF) often represents an opportunity to reassess care goals, treatment intensity, and medication use. We examined changes in glucose-lowering medication (GLM) dispensing following first hospital discharge to LTCFs and whether these changes differed by resident frailty status. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Adults aged ≥65 with type 2 diabetes (T2D) newly discharged to LTCFs in Victoria, Australia, from 2012 and 2018. METHODS: Using linked hospital and medication dispensing data, we compared age- and sex-adjusted prevalence of GLM use in the 90-day period prehospitalization and 90-day period postdischarge to LTCF using Poisson regression. Multivariable adjusted relative risks (aRRs) were estimated using generalized estimating equations. RESULTS: Among 19,704 individuals discharged to an LTCF (78.7% frail, 45.9% aged ≥85 years, 54.6% female), overall GLM use declined from 59.7% (95% CI 58.4-61.0) to 54.8% (95% CI 53.6-56.1) in frail residents, and 59.3% (95% CI 56.9-61.9) to 56.2% (95% CI 53.8-58.7) in robust residents. Changes in age- and sex-adjusted GLM prevalence among frail and robust residents were mainly attributable to decreased use of metformin and sulfonylureas and increased use of insulin. In multivariable-adjusted analyses, frailty was associated with lower likelihood of dispensing metformin monotherapy within 90 days postdischarge (aRR 0.91, 95% CI 0.85-0.97) and metformin plus sulfonylurea at 90 days (aRR 0.89, 95% CI 0.79-0.99). There were no statistically significant differences in aRRs for combination therapy with ≥2 GLMs. In sensitivity analyses, frailty was associated with greater likelihood of no GLM dispensing within 6 months (aRR 1.04, 95% CI 1.02-1.07), but not within 90 days postdischarge (aRR 1.02, 95% CI 1.00-1.05). CONCLUSIONS AND IMPLICATIONS: There are potential missed opportunities to reassess GLM regimens in the 90-day period postdischarge to LTCFs. Resident frailty status did not appear to be associated with meaningful T2D treatment deintensification. Further initiatives may be needed to promote postdischarge medication reviews to optimize diabetes care in this vulnerable population.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Stasinopoulos J, Leung MTY, Yong ASJ, et al. Change in Use of Glucose-Lowering Medications in Frail and Robust Residents Following Hospital Discharge to Long-Term Care Facilities. J Am Med Dir Assoc. 2026. PMID: 41429187. doi:10.1016/j.jamda.2025.106045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。